Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a slight increase of 0.17% and a total trading volume of 1.665 trillion yuan [1]. Group 1: Market Performance - As of 14:59 today, the Shanghai Composite Index stands at 3876.97 points, above the annual line [1]. - A total of 153 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1]. Group 2: Notable Stocks - The stocks with the highest deviation rates include: - Yimin Group (益民集团) with a deviation rate of 9.76% and a daily increase of 10.11% [1]. - Wanrun Technology (万润科技) with a deviation rate of 6.64% and a daily increase of 7.57% [1]. - Laiyifen (来伊份) with a deviation rate of 5.56% and a daily increase of 10.01% [1]. - Other stocks with smaller deviation rates that have just crossed the annual line include Suzhou Planning (苏州规划), Tianzhihang (天智航), and China Railway Special Cargo (中铁特货) [1].

Core Viewpoint - The company is actively advancing its layout in the brain-computer interface field, with specific investment decisions based on strategic development, business line, product tier needs, and actual circumstances [1] Group 1: Product Development - The company has developed a multimodal ADHD behavior treatment system that includes two products: UMind (hospital version) and SE (home version), which facilitate data interconnection between hospital behavior training centers and home training scenarios [1] - The company plans to initially promote the product through professional channels, leveraging both hospital markets and external professional institutions such as Fangcun Doctors and educational organizations to build a professional barrier for the product [1] Group 2: Market Strategy - The company aims to utilize its extensive e-commerce operational experience to empower future consumer-level promotion of the product in the e-commerce sector [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Group 1 - The company announced a joint investment with Jiangsu Yingjue Private Equity Fund Management Co., Ltd. and Jiaxing Silin Venture Capital Partnership to establish Aipeng Zhilian Cloud Brain (Jiaxing) Equity Investment Partnership [1] - The company will act as a limited partner, contributing RMB 49.7 million, which represents a 49.7% stake in the investment fund [1] - The fund will primarily focus on equity investments in areas such as brain-computer interfaces, neuroscience, mental system diseases, and other healthcare sectors, with an investment period of 4 years and a total duration of 7 years [1]

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-053 江苏爱朋医疗科技股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、与专业投资机构合作投资概述 为满足战略发展需求，充分借助专业投资机构的力量及资源优势，加快推动产业 布局优化，在不影响公司日常经营和发展、有效控制投资风险的前提下，江苏爱朋医 疗科技股份有限公司（以下简称"公司"或"爱朋医疗"）与江苏英掘私募基金管理 有限公司、嘉兴思麟创业投资合伙企业（有限合伙）共同签署了《爱朋智链云脑（嘉 兴）股权投资合伙企业（有限合伙）合伙协议》（以下简称"合伙协议"），根据合 伙协议约定，公司作为有限合伙人以自有资金人民币4,970万元出资认购投资基金份 额，出资比例为49.7%。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第7号——交易与关联交易》及《公司章程》等相关规定，上述交易不属于关联 交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组，无需提交 公司董事会及股东会审议。 二、投资基金基 ...

Group 1 - The Jiangxi Provincial Government is accelerating the clinical research of brain-computer interface technology in the treatment of neurological and psychiatric diseases, as well as in elderly rehabilitation [1] - The government supports medical institutions in establishing clinical research wards and cohorts for brain-computer interface technology [1] - The establishment of the Jiangxi Brain-Computer Interface Rehabilitation Center and high-quality data sets for the EEG industry in the Ganjiang New Area is also being promoted [1] Group 2 - Aipeng Medical (300753.SZ) confirmed that its perioperative brain state monitoring product, the anesthesia depth monitor, has generated sales revenue in Jiangxi Province, although the revenue impact is relatively small [1]

Core Viewpoint - Aipeng Medical (300753) is responding to investor inquiries regarding the advancement of brain-computer interface technology in clinical research for neurological and psychiatric diseases, as well as rehabilitation for the elderly in Jiangxi Province [1] Group 1: Company Response - Aipeng Medical has reported that its perioperative brain state monitoring product, the anesthesia depth monitor, has generated sales revenue in Jiangxi Province, although the revenue contribution is relatively small [1] Group 2: Industry Context - The Jiangxi Provincial Government has issued measures to accelerate the development of brain-computer interface technology and industry, emphasizing the need for clinical trials and the establishment of clinical research wards and cohorts in medical institutions [1] - The government supports the construction of a rehabilitation center for brain-computer interfaces and a high-quality data set for the EEG industry in the Ganjiang New Area [1]

Group 1: Industrial Mother Machine Sector - The industrial mother machine sector shows a positive trend with a total index increase of 1.29% to 1754.21 [2] - Key stocks in this sector include: - GuoJi Heavy Industry (601399) with a price of 4.63, up by 9.98% and 42.46% over the past five days [2] - China First Heavy Industries (601106) at 3.42, also up by 9.97% and 13.62% over the last five days [2] - Weihong Co., Ltd. (300508) at 38.12, increasing by 9.29% and 10.05% in five days [2] - Other notable performers include: - Yuhuan CNC (002903) at 24.54, up by 6.70% [2] - Ruineng Technology (603933) at 30.40, with a 5.89% increase [2] Group 2: Brain-Computer Interface Sector - The brain-computer interface sector experienced significant activity, highlighted by the upcoming "Brain Link World, Intelligence Gathering in Shanghai" conference scheduled for December 4-5, 2025 [3] - Key stocks in this sector include: - Dineike (300884) with a price of 16.82, up by 14.34% and 18.09% over the past five days [3] - Nanjing Panda (600775) at 12.55, increasing by 9.99% and 13.78% [3] - Chengyitong (300430) at 18.99, up by 3.94% [3] - Other stocks showing positive movement include: - Beiyikang (920199) at 34.70, up by 3.89% [3] - Innovation Medical (002173) at 22.29, with a 3.05% increase [3]

（文章来源：证券日报） 证券日报网讯 12月2日，爱朋医疗在互动平台回答投资者提问时表示，公司将积极研究国家和地区相关 脑机接口利好政策，抓住政策机遇，推动公司业务发展。 ...